Synonym: (4Z)-7-[(rel-1S,2S,5R)-5-((1,1′-Biphenyl-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]- 4-heptenoic acid hemicalcium salt
CAS Number: 81496-19-7
Empirical Formula (Hill Notation): C29H34NO5 · 0.5 Ca
Molecular Weight: 496.62
MDL Number: MFCD05665139
Linear Formula: C29H34NO5 · 0.5 Ca
Product Type: Chemical
| assay |
≥90% (HPLC) |
| color |
white to beige |
| form |
powder |
| InChI |
1S/2C29H35NO5.Ca/c2*31-26-20-27(35-21-22-12-14-24(15-13-22)23-8-4-3-5-9-23)25(10-6-1-2-7-11-28(32)33)29(26)30-16-18-34-19-17-30;/h2*1-5,8-9,12-15,25,27,29H,6-7,10-11,16-21H2,(H,32,33);/q;;+2/p-2/b2*2-1-;/t2*25-,27-,29+;/m11./s1 |
| InChI key |
JDEBIDDIERGZQY-XVFRBOAOSA-L |
| originator |
GlaxoSmithKline |
| Quality Level |
100  |
| SMILES string |
O=C(C[C@@H](OCC1=CC=C(C2=CC=CC=C2)C=C1)[C@H]3CC/C=CCCC(O[Ca]OC(CC/C=CCC[C@@H]4[C@H](OCC5=CC=C(C6=CC=CC=C6)C=C5)CC([C@H]4N7CCOCC7)=O)=O)=O)[C@H]3N8CCOCC8 |
| solubility |
DMSO: 5 mg/mL, clear |
| |
H2O: insoluble |
| storage temp. |
−20°C |
| Application: |
AH23848 has been used as an prostaglandin E2 receptor 4 (EP4) receptor antagonist to study its effect on cAMP accumulation in monocrotaline (MCT28d) rat pulmonary arterial smooth muscle cells (PASMCs) and human T cell enriched peripheral blood mononuclear cells (PBMC). It has also been used to study its effect on the expressions of collagen-I, metalloproteinase (MMP-1), MMP-3, and EP4 gene expression in human tendon fibroblasts following interleukin (IL)-1β treatment. |
| Biochem/physiol Actions: |
AH23848 regulates nitric oxide (NO) production and reduces endogenous cAMP accumulation. This is carried out by declination of inducible nitric oxide synthase (iNOS) gene expression and acceleration of iNOS protein degradation in glomerular mesangial cells. |
| Biochem/physiol Actions: |
EP4 prostanoid receptor antagonist with TP blocking activity. |
| Features and Benefits: |
This compound is featured on the Prostanoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: |
This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
5, 25 mg in glass bottle |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥90% (HPLC) |
| Storage Temp. |
−20°C |
| UNSPSC |
12352200 |
